Physician
Providence Health & Services - Oregon
Providence Health & Services - Oregon was paid $49.08M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 99285, emergency room visit (most serious) — 32% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES - OREGON
PORTLAND, OR 97213
PORTLAND, OR 97213
33aNPI1003991845assigned 10/26/2006
33bProvider typeAnesthesiology Physician
28Total paid$49.08M
24GClaims736,141
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Oregon
Rank by total paid#1 of 43
Median peer was paid$94K
This provider vs. median523×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 149,890 | $10.50M | |
| 2019 | 101,696 | $6.28M | |
| 2020 | 91,152 | $6.15M | |
| 2021 | 120,375 | $6.01M | |
| 2022 | 119,288 | $6.65M | |
| 2023 | 89,030 | $7.01M | |
| 2024incomplete | 64,710 | $6.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 32% | 48,878 | 41,822 | $15.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 47,597 | 39,759 | $12.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 43,342 | 36,372 | $7.17M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.9% | 60,185 | 53,087 | $2.91M |
| S9480 | Intensive outpatient psychiatric services, per diem | 4.7% | 11,073 | 2,357 | $2.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.0% | 30,818 | 23,288 | $1.95M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 14,373 | 12,867 | $1.43M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 12,395 | 2,951 | $465K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 5,011 | 1,983 | $459K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,525 | 277 | $363K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 4,927 | 979 | $351K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,477 | 4,258 | $332K |
159 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 33,729 | $327K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,730 | $291K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,460 | $228K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,471 | $188K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,898 | $126K |
| 80053 | Comprehensive metabolic panel | <1% | 95,797 | $122K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,903 | $119K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,058 | $112K |
| 11043 | <1% | 439 | $112K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,261 | $102K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,885 | $96K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,332 | $79K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 107,126 | $76K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,322 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,806 | $66K |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,993 | $64K |
| 80061 | Lipid panel | <1% | 9,728 | $62K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 793 | $62K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,100 | $58K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 1,677 | $55K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 988 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,504 | $46K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 31 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,707 | $32K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 726 | $32K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,340 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,723 | $29K |
| 88342 | <1% | 563 | $28K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 185 | $20K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 40 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 65 | $17K |
| 87522 | Neg quan hep c or qual rna | <1% | 539 | $14K |
| 84439 | <1% | 2,066 | $13K | |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 12 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,234 | $12K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 57 | $12K |
| 85027 | <1% | 3,116 | $10K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 147 | $9K |
| H0048 | Alcohol and/or other drug testing: collection and handling only, specimens other than blood | <1% | 451 | $9K |
| 82105 | <1% | 1,061 | $9K | |
| H0001 | Alcohol and/or drug assessment | <1% | 75 | $9K |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 298 | $8K |
| 87070 | <1% | 1,296 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 231 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,074 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 57 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 36 | $7K |
| 88142 | <1% | 387 | $6K | |
| 82728 | <1% | 757 | $6K | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 27 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 213 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,233 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 52 | $4K |
| 86803 | <1% | 683 | $4K | |
| 96415 | <1% | 103 | $4K | |
| 87510 | <1% | 475 | $4K | |
| 88141 | <1% | 170 | $4K | |
| 82570 | <1% | 773 | $4K | |
| 80076 | <1% | 1,431 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 213 | $3K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $3K |
| 87660 | <1% | 475 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 26 | $3K |
| 82565 | <1% | 1,819 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 229 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 116 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 104 | $3K |
| 80050 | General health panel | <1% | 402 | $3K |
| 82247 | <1% | 1,114 | $3K | |
| 84484 | <1% | 10,296 | $3K | |
| 86003 | <1% | 43 | $3K | |
| 87480 | <1% | 475 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 260 | $2K |
| 73564 | <1% | 37 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 81 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $2K |
| 87517 | <1% | 74 | $2K | |
| 82607 | <1% | 162 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 85 | $1K |
| 85610 | <1% | 1,053 | $1K | |
| 81001 | <1% | 5,223 | $1K | |
| 83516 | <1% | 185 | $1K | |
| 83690 | <1% | 3,169 | $1K | |
| 88360 | <1% | 51 | $971.26 | |
| 82172 | <1% | 60 | $850.76 | |
| 84134 | <1% | 2,529 | $803.07 | |
| 83550 | <1% | 172 | $671.79 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $651.72 |
| 88312 | <1% | 28 | $650.78 | |
| 86706 | <1% | 94 | $637.45 | |
| 83735 | <1% | 2,849 | $618.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,283 | $575.73 |
| 73502 | <1% | 12 | $562.04 | |
| 87340 | <1% | 85 | $557.82 | |
| 83540 | <1% | 185 | $546.59 | |
| 86704 | <1% | 61 | $532.60 | |
| 83883 | <1% | 57 | $439.97 | |
| 84153 | <1% | 68 | $416.48 | |
| 84460 | <1% | 177 | $397.93 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 66 | $368.00 |
| 84450 | <1% | 163 | $358.28 | |
| 82670 | <1% | 12 | $314.64 | |
| 82785 | <1% | 43 | $314.43 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,808 | $297.72 |
| 86140 | <1% | 149 | $295.98 | |
| 84100 | <1% | 2,687 | $274.69 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $260.04 |
| 85652 | <1% | 212 | $252.99 | |
| 81025 | <1% | 854 | $248.00 | |
| 84165 | <1% | 80 | $247.46 | |
| 77077 | <1% | 15 | $243.26 | |
| 82977 | <1% | 60 | $227.66 | |
| 87205 | <1% | 111 | $219.60 | |
| 86038 | <1% | 28 | $216.18 | |
| 80305 | <1% | 376 | $205.25 | |
| 88304 | <1% | 13 | $203.28 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 12 | $162.10 |
| 82043 | <1% | 63 | $161.90 | |
| 80159 | <1% | 37 | $128.96 | |
| 84520 | <1% | 57 | $126.59 | |
| 87081 | <1% | 27 | $123.63 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,175 | $116.00 |
| 86708 | <1% | 13 | $99.28 | |
| 86705 | <1% | 12 | $96.64 | |
| 87186 | <1% | 15 | $77.93 | |
| 80069 | <1% | 89 | $76.34 | |
| 82378 | <1% | 17 | $64.48 | |
| 83970 | <1% | 28 | $63.74 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,368 | $63.09 |
| 86431 | <1% | 12 | $53.13 | |
| 83615 | <1% | 57 | $48.00 | |
| 83605 | <1% | 243 | $41.50 | |
| 84156 | <1% | 43 | $29.04 | |
| 83880 | <1% | 172 | $27.00 | |
| 64483 | <1% | 14 | $17.63 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 423 | $3.26 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 7,087 | $0.02 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,912 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 72 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 197 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 53 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 110 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 76 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 53 | $0.00 |
| C7902 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, each additional 15 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service (list separately in addition to code for primary service) | 0% | 239 | $0.00 |
| 96376 | 0% | 29 | $0.00 | |
| 84703 | 0% | 40 | $0.00 | |
| 88341 | 0% | 12 | $0.00 | |
| 83521 | 0% | 17 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 23 | $0.00 |
| 87486 | 0% | 12 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| 87581 | 0% | 12 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 987 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 42 | $0.00 |
| 84145 | 0% | 29 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 75 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Parent organizationPROVIDENCE HEALTH & SERVICES - OREGON
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.